Understand the source comparison
SS-LUP-332 for Men: Clinical Research and Metabolic Studies Comparison
Acute metabolic challenge (Nature Metabolism 2024) Male rodents, 12 weeks old, C57BL/6 strain 10mg/kg IP single dose Palmitate oxidation rate in skeletal muscle 37% increase vs vehicle at 90 min post-dose Demonstrates rapid onset. Useful for acute substrate-sw
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Acute metabolic challenge (Nature Metabolism 2024)
- Male rodents, 12 weeks old, C57BL/6 strain
- 10mg/kg IP single dose
- Palmitate oxidation rate in skeletal muscle
- 37% increase vs vehicle at 90 min post-dose
- Demonstrates rapid onset. Useful for acute substrate-switching studies
- Multi-week endurance protocol (J Appl Physiol 2025)
- Male humans, n=14, age 35–42, recreationally active
- 150mg oral daily × 6 weeks
- Mitochondrial density (EM), lactate threshold
- 18% mitochondrial density increase, 9% lactate threshold improvement
- First human data. Shows feasibility but needs larger cohort for variance
- Hepatic lipid reduction study (Metabolism 2024)
- Male rodents, diet-induced obesity model
- 15mg/kg IP daily × 4 weeks
- Hepatic triglyceride content (biopsy + MRI)
- 31% reduction in liver TG vs 12% diet-only control
- Suggests therapeutic relevance for NAFLD. Androgen dependency unconfirmed
- Sex-stratified AMPK response (Endocrinology 2024)
- Males (n=21) and females (n=21), matched BMI
- 1.5mg/kg oral single dose
- Indirect calorimetry (fat oxidation rate)
- Males: 22% higher fat oxidation vs females at equivalent dose
- Confirms sex-specific response. Likely androgen-mediated but needs mechanistic follow-up